Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936803 | 1.00 | CYP4F2 (0.46) | CYP4F2CYP4A11ALDH1A1NAMPTCYP3A4 | |
| SCHEMBL8562391 | 0.89 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1CYP3A4CYP2D6 | |
| Propyliodone SCHEMBL28142146 | 0.83 | ALDH1A1 (0.36) | CYP4F2CYP4A11ALDH1A1NAMPTPPARG | |
| Iophendylate SCHEMBL492663 | 0.78 | CYP4F2 (0.42) | CYP4F2CYP4A11ALDH1A1NAMPTCYP3A4 | |
| SCHEMBL27599795 | 0.77 | CSNK1E (0.37) | ALDH1A1PPARGTSHRKMT2A | |
| SCHEMBL7708867 | 0.75 | CYP3A4 (0.53) | CYP4F2CYP4A11ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL28162700 | 0.74 | NLRP3 (0.42) | CYP4F2CYP4A11ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL711239 | 0.73 | CYP3A4 (0.52) | CYP4F2CYP4A11ALDH1A1NAMPTCYP3A4 | |
| SCHEMBL26970783 | 0.73 | PRSS1 (0.43) | ALDH1A1CYP3A4PPARGTDP1TSHR | |
| SCHEMBL9469153 | 0.72 | CYP4F2 (0.50) | CYP4F2CYP4A11ALDH1A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170280-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| US-20250170279-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| US-20210145747-A1 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2021-05-20 | — | — | US | claimed |
| US-20200397926-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2020-12-24 | — | — | US | claimed |
| EP-3744317-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Inno Medicine Co., Ltd. (CN) | 2020-12-02 | — | — | EP | claimed |
| US-10600524-B2 | Radiation protection device and methods thereof | STEMRAD LTD. (IL) | 2020-03-24 | — | — | US | claimed |
| EP-3610859-A1 | CERASOME DELIVERY SYSTEM FOR USE IN TARGETED ACTIVATION OF CD44 MOLECULE, PREPARATION METHOD THEREFOR AND USE | Beijing Inno Medicine Co., Ltd. (CN) | 2020-02-19 | — | — | EP | claimed |
| CN-110402137-A | A kind of silica nodule delivery system, preparation method and use for targeted activation CD44 molecule | BEIJING INNO MEDICINE CO LTD | 2019-11-01 | — | — | CN | claimed |
| CN-105013017-B | A kind of minimally invasive orthopaedics implant compositions | 爱本斯南京医疗器械有限公司 | 2019-08-16 | — | — | CN | claimed |
| EP-2706881-B1 | RADIATION PROTECTION DEVICE AND METHODS THEREOF | STEMRAD LTD (IL) | 2018-07-25 | — | — | EP | claimed |
| EP-0414806-A4 | HIGH RATIO ACTIVE AGENT:LIPID COMPLEX | — | 1991-11-13 | — | — | EP | claimed |
| EP-0414806-A1 | HIGH RATIO ACTIVE AGENT:LIPID COMPLEX. | LIPOSOME CO INC (US) | 1991-03-06 | — | — | EP | claimed |
| EP-0165994-B1 | CONTRAST AGENTS AND METHOD OF USE THEREOF | RUBIN, Daniel Lee (US) | 1990-07-18 | — | — | EP | claimed |
| WO-1989011272-A1 | HIGH RATIO ACTIVE AGENT:LIPID COMPLEX | THE LIPOSOME COMPANY, INC. (US) | 1989-11-30 | — | — | WO | claimed |
| EP-0165630-B1 | METHOD OF PREPARING A CHLORINATED, BROMINATED, RADIOBROMINATED, IODINATED AND/OR RADIOIODINATED, AROMATIC OR HETEROAROMATIC COMPOUND, AS WELL AS A KIT FOR PREPARING A DIAGNOSTIC COMPOSITION ON THE BASIS OF THIS COMPOUND | MALLINCKRODT, INC.(a Missouri corporation) (US) | 1989-10-18 | — | — | EP | claimed |
| EP-0165994-A4 | CONTRAST AGENTS AND METHOD OF USE THEREOF. | RUBIN DANIEL LEE | 1986-11-07 | — | — | EP | claimed |
| EP-0165994-A1 | CONTRAST AGENTS AND METHOD OF USE THEREOF. | RUBIN DANIEL LEE | 1986-01-02 | — | — | EP | claimed |
| EP-0165630-A2 | Method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radioiodinated, aromatic or heteroaromatic compound, as well as a kit for preparing a diagnostic composition on the basis of this compound | MALLINCKRODT, INC.(a Missouri corporation) (US) | 1985-12-27 | — | — | EP | claimed |
| WO-1985003004-A1 | CONTRAST AGENTS AND METHOD OF USE THEREOF | RUBIN DANIEL LEE | 1985-07-18 | — | — | WO | claimed |
| US-4192859-A | MEDICAL DIAGNOSIS USING X-RAYS | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145747-A1 | CERASOME DELIVERY SYSTEM FOR TARGETING ACTIVATED CD44 MOLECULE, PREPARATION METHOD AND USE THEREOF | CD44, LDLR, PLAUR | CYP4F2 4744/4885CYP4A11 3295/4885ALDH1A1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.